Lu S, Zhou Q, Liu X, Du Y, et al. Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China. J Thorac Oncol 2022 Mar 17. pii: S1556-0864(22)00147.
PMID: 35307611